Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T07:58:11.551Z Has data issue: false hasContentIssue false
  • English
  • Français

Serelaxin for infant heart failure in congenital dilated cardiomyopathy

Published online by Cambridge University Press:  15 January 2018

Patrick O. Myers ,
Alice Bordessoule  and
Cécile Tissot
Patrick O. Myers*
Affiliation:
Cardiovascular Surgery, Geneva University Hospitals & Faculty of Medicine Geneva, Switzerland
Alice Bordessoule
Affiliation:
Pediatric Intensive Care, Children’s University Hospital Geneva & Faculty of Medicine, Geneva, Switzerland
Cécile Tissot
Affiliation:
Unit of Pediatric Cardiology, Children’s University Hospital Geneva & Faculty of Medicine, Geneva, Switzerland
*
Author for correspondence: P. O. Myers, MD, Division of Cardiovascular Surgery, Geneva University Hospitals & School of Medicine, 4 rue Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. Tel: +41 22 372 7638; Fax: +41 22 372 7634; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Serelaxin has been studied in trials in adults with acute heart failure, but not in children. We report the first compassionate use of serelaxin in an infant. A 6-month-old girl with dilated cardiomyopathy was placed on extracorporeal membrane oxygenation following cardiac arrest unresponsive to medical treatment. Extracorporeal membrane oxygenation weaning failed despite maximal ino-dilator therapy. During the 48-hour infusion of serelaxin, we observed marked improvement in brain natriuretic peptide, left ventricular systolic function, and dilatation. The patient was successfully weaned from extracorporeal membrane oxygenation 24 hours later. The child died after a second extracorporeal membrane oxygenation run owing to sepsis.

Keywords

Heart failureCHDinotropic/vasoactive drugs
Type
Brief Report
Information
Cardiology in the Young , Volume 28 , Issue 5 , May 2018 , pp. 734 - 736
Check for updates
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Teerlink, JR, Cotter, G, Davison, BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29–39.CrossRefGoogle ScholarPubMed
2. Teerlink, JR, Metra, M, Felker, GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429–1439.CrossRefGoogle ScholarPubMed
3. Metra, M, Cotter, G, Davison, BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196–206.Google Scholar
4. Ponikowski, P, Mitrovic, V, Ruda, M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Hear J 2014; 35: 431–441.Google Scholar
5. Hoffman, TM, Wernovsky, G, Atz, AM, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107: 996–1002.CrossRefGoogle ScholarPubMed